Bapineuzumab

Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) [1][2].

Product Specifications

CAS Number

[648895-38-9]

UNSPSC

12352203

Target

Amyloid-β

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/bapineuzumab.html

Purity

96.62

Solubility

10 mM in DMSO

Smiles

[Bapineuzumab]

Molecular Weight

(144.5 kDa)

References & Citations

[1]Stephen Salloway, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370 (4) :322-33.|[2]Fuller, J. P., et al., (2015) . Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies. Acta neuropathologica, 130 (5), 699–711.